MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • MDS Virtual Congress 2020

    Comparison of the effect of hydroalcoholic extract of olive leaf and levodopa on reducing parkinson’s symptoms in animal model

    M. Modaresi (Isfahan, Islamic Republic of Iran)

    Objective: Today, the use of medicinal herbs to prevent and slow down the progression of Parkinson's disease has attracted the attention of researchers. The phenolic…
  • MDS Virtual Congress 2020

    Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy

    T. Birnberg, G. Smania, M. Bjornsson, N. Jonsson, R. Case, S. Oren, L. Adar, M. Karlsson (Rehovot, Israel)

    Objective: To develop population pharmacokinetic (PK) models for levodopa (LD) and carbidopa (CD) following subcutaneous (SC) infusion, including adjunct oral LD/CD administration. Background: ND0612 is…
  • MDS Virtual Congress 2020

    Efficacy of opicapone in different levodopa-containing treatment regimens in Parkinson’s disease patients with motor fluctuations

    A. Antonini, G. Ebersbach, O. Rascol, F. Ikedo, D. Magalhães, J.F Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations being treated with different levodopa-containing treatment regimens. Background: OPC,…
  • MDS Virtual Congress 2020

    All-cause mortality in pimavanserin and atypical antipsychotic users with Parkinson’s disease in Medicare

    A. Mosholder, Y. Ma, S. Akhtar, G. Podskalny, Y. Wei, J. Liao, Y. Feng, H. Lyu, M. Wernecke, K. Leishear, L. Nelson, T. MaCurdy, J. Kelman, D. Graham (Silver Spring, MD, USA)

    Objective: To assess all-cause mortality in Medicare beneficiaries with Parkinson’s disease (PD)  receiving pimavanserin or atypical antipsychotics (AAs). Background: In PD patients, the lifetime prevalence…
  • MDS Virtual Congress 2020

    Apomorphine Sublingual Film for On-Demand Treatment of “OFF” Episodes in Patients With Parkinson’s Disease: Impact of Concomitant Antiemetics and Dopamine Agonists on Nausea and Vomiting

    A. Ellenbogen, A. Nicholas, R. Hauser, P. Bhargava, E. Pappert, B. Navia (Farmington Hills, MI, USA)

    Objective: Analyze effect of concomitant antiemetics and dopamine agonists (DA) on nausea and vomiting (N/V) in patients receiving apomorphine sublingual film (APL-130277; APL) for on-demand…
  • MDS Virtual Congress 2020

    Super-Responders to Opicapone Adjunct Treatment to Levodopa in Parkinson’s Disease Patients with Motor Fluctuations: Combined Post-Hoc Analysis of BIPARK-I and II

    A. Antonini, W. Poewe, J. Ferreira, G. Ebersbach, H. Gama, J.F Rocha, D. Magalhães, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the efficacy and safety of opicapone (OPC) in Parkinson’s disease (PD) patients who were considered ‘super-responders’ (>= 2 hours of OFF-time reduction…
  • MDS Virtual Congress 2020

    New compound increasing glucocerebrosidase activity on primary cell cultures obtained from patients with GBA-associated Parkinson’s disease

    M. Nikolaev, A. Kopytova, K. Senkevich, G. Baydakova, I. Miliukhina, E. Zakharova, G. Rychkov, A. Cheblokov, F. Ibatullin, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

    Objective: To determine whether new chemical modifications of the previously described allosteric GCase chaperone N607 (Aflaki E et.al Neurosc. 2016) increase GCase activity in monocyte-derived…
  • MDS Virtual Congress 2020

    Safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, as a function of baseline dyskinesia (BL-dyskinesia) in Parkinson’s disease (PD): A pooled analysis of 4 studies

    L. Elmer, K. Toyama, J. Parno, D. Braccia, R. Ristuccia, A. Mori (Toledo, OH, USA)

    Objective: To evaluate the effect of BL-dyskinesia on the efficacy and safety of istradefylline in 4 randomized, placebo-controlled, double-blind, phase 2b/3 trials. Background: Istradefylline, a…
  • MDS Virtual Congress 2020

    Positive Correlations Between Quality of Life and Sleep Dysfunction in Advanced Parkinson’s Disease Patients Prior to and After 12 Months of Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis From the DUOGLOBE Study

    K.R Chaudhuri, J. Boyd, E. Cubo, I. Malaty, F. Pontieri, M. Simu, L. Bergmann, T. Gao, Y. Jalundhwala, P. Kukreja, J. Aldred (London, United Kingdom)

    Objective: To evaluate the relationship between sleep disturbances and quality of life (QoL) in advanced Parkinson’s disease (PD) patients both prior to and at month…
  • MDS Virtual Congress 2020

    Pharmacokinetics of Levodopa in patients with Parkinson’s disease: Efforts toward a predictive model

    N. Nishikawa, H. Iwaki, T. Shiraishi, Y. Mukai, Y. Takahashi, N. Hattori (Kodaira, Japan)

    Objective: Our aim was to explore correlations between the pharmacokinetics of levodopa (LD) and clinical manifestation in patients with Parkinson’s disease (PD). Our goal was…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 34
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley